BACKGROUND: Flufenamic acid is a member of the fenamates and is used as an analgesic and NSAID drug. According to the ability of this drug on blocking connexin and preventing leakage of substances such as ATP from cells, it seems to be beneficial in healing diabetic wounds. OBJECTIVES: Evaluation of the effects of topical flufenamic acid as a connexin-channel blocker on skin wound healing in alloxan-induced diabetic rats. METHODS: In this study diabetics was induced in 40 male rats by IP injection of 150mg/kg of alloxan and they were divided to 4 groups. After anesthesia, 2×2 cm incision was made on the back of the rats and the skin was separated completely. Three groups were treated by 2, 5 and 10 percent concentration of flufenamic acid ointment separately, and one group was treated by Vaseline and ucerine ointment as control. Bandage and ointment were changed daily and the procedure was carried out for 21 days. The wound surface was measured on odd days. Half of the rats of each group on day five and half of them on day 21 were euthanized to get pathologic slides. RESULTS: Process of healing, fibroblast concentration, epithelialization, angiogenesis, collagen formation and wound closure in 2 percent group were better than other groups and in control, 5 and 10 percent groups had a decreasing trend respectively and had a significant difference. In the last two groups, the healing process was disrupted. CONCLUSIONS: The 2 percent concentration of drug not only did not show potent anti-inflammatory effects, but also improved the process of healing by blocking the connexin 43 and inhibition of ATP release, while in the concentration of 5 and 10 percent, anti-inflammatory effects of the drug predominated and delayed the healing process.

Objectives: Aqueous extracts of Rhizophora mucronata and Avicennia marina leaves were inves¬tigated for their hepatoprotective potential in diabetic rats. Materials and methods: One hundred twenty male albino rats were randomly assigned to eight equal groups (n = 15). The first group (control) comprised normal healthy rats, while the second to fifth groups were intraperitoneally injected with a single dose of streptozotocin (STZ) [60 mg/ kg body weight (BW)] for induction of diabetes. Group 2 was kept as positive diabetic control, while groups 35 were orally treated with aqueous extracts of R. mucronata (400 mg/kg BW), A. marina (400 mg/kg BW) and with a combination of ½ a dose of the two plants, respectively, for six weeks. Groups 68 were non-diabetic rats that orally received aqueous extracts of R. mucronata (400 mg/kg BW), A. marina (400 mg/kg BW), and a combination of ½ a dose of the two plants, respectively, for 6 weeks. Results: STZ-induced diabetic rats showed a significant reduction in serum glucose and liver enzymes, increased serum insulin, Homeostasis Model Assessment of β-cells (HOMA-β), and Homeostasis Model Assessment of Insulin Resistance (HOMA-IR). Histopathological and immuno¬histochemical examinations of the liver revealed improved pathologic criteria in the plant extract treated diabetic rats compared with the remarkable changes which had been seen in STZ-induced diabetic rats. Conclusion: This study suggests that the aqueous extract of R. mucronata or its combination with A. marina showed potent hypoglycemic and hepatoprotective effects for liver dysfunction, as well as histopathological and immunohistochemical changes in the liver of STZ-induced diabetic rats. [J Adv Vet Anim Res 2020; 7(1.000): 177-185]